Corline Biomedical
Corline Biomedical: Q4 Review (Redeye)
2021-03-01 10:08
Redeye reiterates its positive view and Base case of SEK 39 per share following Corline’s Q4 report. We provide a brief comment on the financials and highlight the most important events during the period.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se